Is there a role for rituximab in the treatment of spondyloarthritis and psoriatic arthritis?

Journal of Rheumatology

Volumn 39, Issue 12, 2012, Pages 2235-2237

  Mease, Philip J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR ANTIBODY; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

B LYMPHOCYTE; DACTYLITIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EDITORIAL; ENTHESITIS; EYE INFLAMMATION; HUMAN; JOINT SWELLING; MUSCULOSKELETAL DISEASE; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SPONDYLARTHRITIS; SPONDYLITIS; SYNOVITIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE; SPONDYLITIS, ANKYLOSING;

EID: 84869480164     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121149     Document Type: Editorial

References (14)

1. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
2. Wendling D, Dougados M, Berenbaum F, Brocq O, Schaeverbeke T, Mazieres B, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012;39:2327-31.
3. Mease PJ. Psoriatic arthritis: Update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70:i77-84.
4. Ronneberger M, Schett G. Pathophysiology of spondyloarthritis. Curr Rheumatol Rep 2011;13:416-20.
5. De Rycke L, Kruithof E, Vandooren B, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: Insights from synovial membrane studies. Curr Rheumatol Rep 2006;8:275-82. (Pubitemid 44623954)
6. Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66:720-6. (Pubitemid 46846689)
7. Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008;58:730-3. (Pubitemid 351364870)
8. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8. (Pubitemid 47237290)
9. Mielke F, Schneider-Obermeyer J, Dorner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-7. (Pubitemid 351956683)
10. Hardcastle SA, Gibbs S, Williamson L. Atypical psoriasis following rituximab for rheumatoid arthritis. J Rheumatol 2012;39:1303-4.
11. Markatseli TE, Kaltsonoudis ES, Voulgari PV, Zioga A, Drosos AA. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin Exp Rheumatol 2009;27:996-8.
12. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial. Arthritis Rheum 2012;62:1290-7.
13. Mease P, Kavanaugh A, Genovese M, Ritchlin C, Rosengren S, Quistberg A, et al. Rituximab in psoriatic arthritis provides modest clinical improvement and reduces expression of inflammatory biomarkers in skin lesions [abstract]. Arthritis Rheum 2010;62 Suppl:S818.
14. Jimenez-Boj E, Stamm TA, Sadlonova M, Rovensky J, Raffayova H, Leeb B, et al. Rituximab in psoriatic arthritis: An exploratory evaluation. Ann Rheum Dis 2012 July 24. (Epub ahead of print).